Evidence map›Paper›PMID 34948123›Full record

ArticleInternational journal of molecular sciences2021

Increased Susceptibility of the CD57

Anastasia I Palamarchuk, Nadezhda A Alekseeva, Maria A Streltsova, Maria O Ustiuzhanina, Polina A Kobyzeva, Sofya A Kust, Maria V Grechikhina, Anna A Boyko, Olga A Shustova, Alexander M Sapozhnikov and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Anastasia I PalamarchukShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Nadezhda A AlekseevaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Maria A StreltsovaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.ORCID 0000-0002-5403-0753
Maria O UstiuzhaninaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.ORCID 0000-0003-3378-6508
Polina A KobyzevaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Sofya A KustShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.ORCID 0000-0001-6365-0279
Maria V GrechikhinaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Anna A BoykoShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Olga A ShustovaShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Alexander M SapozhnikovShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.
Elena I KovalenkoShemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, st. Miklukho-Maklaya, 16/10, 117997 Moscow, Russia.ORCID 0000-0001-8119-8247
Institute of Bioorganic Chemistry · RUSkolkovo Institute of Science and Technology · RU

Funding

Russian Science Foundation 21-74-30016
6 · The paper itself

Abstract

Nowadays, the use of genetically modified NK cells is a promising strategy for cancer immunotherapy. The additional insertion of genes capable of inducing cell suicide allows for the timely elimination of the modified NK cells. Different subsets of the heterogenic NK cell population may differ in proliferative potential, in susceptibility to genetic viral transduction, and to the subsequent induction of cell death. The CD57

Indexed as

Cell ProliferationCRISPR-Cas SystemsGene Expression RegulationGenetic VectorsLymphocyte ActivationRetroviridaeTransduction, GeneticCell DeathHumansK562 CellsKiller Cells, NaturalNK Cell Lectin-Like Receptor Subfamily CReceptors, KIR2DL2Receptors, KIR2DL3KIR2DL2 protein, humanKIR2DL3 protein, humanKLRC2 protein, humanNK Cell Lectin-Like Receptor Subfamily CReceptors, KIR2DL2Receptors, KIR2DL3adoptive NK cellsgenetic modificationsHLA-DRiCasp9 geneNK cellsproliferationretroviral vectorssuicide switchtransduction

Identifiers

PMID34948123
PMCPMC8709225
OpenAlexW4200234896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.